Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Declines By 17.1%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totaling 220,322 shares, a drop of 17.1% from the December 15th total of 265,860 shares. Based on an average daily volume of 157,036 shares, the short-interest ratio is currently 1.4 days. Approximately 1.4% of the shares of the stock are sold short. Approximately 1.4% of the shares of the stock are sold short. Based on an average daily volume of 157,036 shares, the short-interest ratio is currently 1.4 days.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ALLR shares. Ascendiant Capital Markets upped their price objective on Allarity Therapeutics from $9.25 to $9.50 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.50.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in Allarity Therapeutics by 49.3% during the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after buying an additional 16,729 shares during the period. Jane Street Group LLC bought a new position in shares of Allarity Therapeutics during the second quarter valued at about $27,000. XTX Topco Ltd bought a new position in shares of Allarity Therapeutics during the second quarter valued at about $51,000. Citadel Advisors LLC purchased a new stake in shares of Allarity Therapeutics during the third quarter worth about $149,000. Finally, Capital Advisors Inc. OK bought a new stake in shares of Allarity Therapeutics in the fourth quarter worth about $108,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

Allarity Therapeutics Stock Performance

ALLR opened at $1.18 on Monday. The company has a market cap of $18.64 million, a P/E ratio of -2.00 and a beta of 0.23. The business’s 50-day moving average price is $1.13 and its 200-day moving average price is $1.26. Allarity Therapeutics has a 12 month low of $0.61 and a 12 month high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last issued its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.04. Equities research analysts forecast that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.